In the this session, we will discuss the licensing of IP rights (IPR), with a special focus on cross-border licensing issues between the United States and Latin America, specifically Brazil and Argentina. The Web conference will address the following topics:
- Enforcement Strategies — Comparing enforcement strategies and best practices in each jurisdiction
- Governing Law and Dispute Resolution — Discussion of key considerations in determining choice of law and venue
- Payment of Royalties — Providing examples of different structures and identifying important restrictions in certain jurisdictions
- Tax Issues — Explaining the tax benefits and pitfalls in the licensing of IPR
Speakers
- Laura Ganoza, Partner, Foley & Lardner LLP
- Diego Fernandez, visiting foreign counsel, Foley & Lardner LLP; Senior Associate, Marval, O’Farrell & Mairal, Argentina
- Fábio Luiz Barboza Pereira, Partner, Veirano Advogados
There is no cost to participate in this program, but pre-registration is required. We look forward to having you join us. For more information, please contact Jackie Polson at jpolson@foley.com.
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.